weishuntinib

Weishuntinib (also known as LS-007) is an orally bioavailable, small-molecule multi-kinase inhibitor developed by Guangzhou Liushun Biotechnology. It is designed to target key signaling pathways involved in tumor angiogenesis, proliferation, and the tumor microenvironment. Specifically, it acts as an inhibitor of the Vascular Endothelial Growth Factor Receptors (VEGFR1, 2, and 3), Fibroblast Growth Factor Receptors (FGFR1, 2, and 3), and Platelet-Derived Growth Factor Receptors (PDGFRα and β). By simultaneously blocking these tyrosine kinases, Weishuntinib aims to suppress tumor vascularization and overcome resistance mechanisms associated with single-pathway inhibition. The drug is currently undergoing Phase II clinical evaluation in China for the treatment of unresectable locally advanced recurrent or metastatic esophageal squamous cell carcinoma (ESCC) in patients who have failed prior systemic therapies, including PD-1 inhibitors and chemotherapy.

Other names

Weishuntinib